Physician profile
Jesus Baeza
NPI 1750616462
$10,591.76
in general payments reported to CMS, 2019-2025
28 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,354 · 2020: $358 · 2021: $464 · 2022: $452 · 2023: $449 · 2024: $201 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.35 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,006.10 | 2019-2022 | |
| Abbvie INC. | $590.73 | 2019-2025 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $337.52 | 2019-2025 | |
| Exeltis, USA INC. | $250.33 | 2021-2025 | Slynd |
| Avion Pharmaceuticals | $223.90 | 2019-2023 | Balcoltra |
| Astellas Pharma US INC | $148.30 | 2023-2024 | Veozah |
| Therapeuticsmd, INC. | $119.01 | 2019-2022 | |
| Coopersurgical, INC. | $108.23 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $89.07 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $73.20 | 2022 | |
| Mayne Pharma Commercial LLC | $64.17 | 2025 | |
| Hologic Sales and Service, LLC | $62.38 | 2019-2022 | |
| Sage Therapeutics, LLC | $58.43 | 2024-2025 | Zurzuvae |
| Lupin INC. | $57.32 | 2019-2020 | |
| Shield Therapeutics INC | $46.43 | 2023-2025 | Accrufer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $40.28 | 2023 | Myrisk |
| Pfizer INC. | $40.01 | 2024-2025 | |
| Acessa Health INC. | $37.53 | 2020 | |
| Vertical Pharmaceuticals, LLC | $34.46 | 2019 | |
| Merck Sharp & Dohme LLC | $31.75 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $31.37 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.51 | 2025 | Qelbree |
| Baxter Healthcare | $29.05 | 2022 | |
| Alydia Health | $22.62 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.98 | 2019 | |
| Smith+Nephew, INC. | $14.23 | 2023 | Pico 14 |
| Agile Therapeutics, INC. | $14.15 | 2023 | Twirla |
| Mission Pharmacal Company | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Baeza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.